

Updated results from MONALEESA-2, a phase III trial of
versus placebo plus letrozole in hormone receptor-positive
breast cancer

Annals of Oncology

29, 1541-1547

DOI: [10.1093/annonc/mdy155](https://doi.org/10.1093/annonc/mdy155)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | ABC4 Consensus: Assessment by a German Group of Experts. Breast Care, 2018, 13, 48-58. | 0.8 | 7 |
| 2 | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib+â€%+â€%letrozole: results from MONALEESA-2. Breast Cancer Research and Treatment, 2018, 170, 535-545. | 1.1 | 68 |
| 4 | Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer â€“ the SONIA study: study protocol for a randomized controlled trial. BMC Cancer, 2018, 18, 1146. | 1.1 | 36 |
| 5 | Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559. | 1.4 | 5 |
| 6 | Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880961. | 1.4 | 44 |
| 7 | Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 3-11. | 0.7 | 4 |
| 8 | Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2â€“nonâ€“amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 12-21. | 0.7 | 1 |
| 9 | CDK4-6 inhibitors in breast cancer: current status and future development. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1-16. | 1.5 | 23 |
| 10 | CDK4/6 inhibitors as neoadjuvant treatment in breast cancerâ€”what can we learn?. Annals of Oncology, 2018, 29, 2274-2278. | 0.6 | 4 |
| 11 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2018, 379, 1926-1936. | 13.9 | 805 |
| 12 | Ribociclib in premenopausal women with advanced breast cancer. Lancet Oncology, The, 2018, 19, 850-852. | 5.1 | 2 |
| 13 | Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2â” advanced or metastatic breast cancer. Current Medical Research and Opinion, 2018, 34, 2143-2150. | 0.9 | 7 |
| 14 | CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Research and Treatment, 2018, 172, 9-21. | 1.1 | 52 |
| 15 | Hormone Receptorâ€“Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines. Current Oncology, 2018, 25, 131-141. | 0.9 | 31 |
| 16 | Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. Frontiers in Oncology, 2018, 8, 308. | 1.3 | 62 |
| 17 | The role of abemaciclib in treatment of advanced breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877692. | 1.4 | 14 |
| 18 | 4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017. Geburtshilfe Und Frauenheilkunde, 2018, 78, 469-480. | 0.8 | 3 |
| 22 | Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. American Journal of Health-System Pharmacy, 2019, 76, 1183-1202. | 0.5 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 23 | First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. <i>Clinical Breast Cancer</i> , 2019, 19, e701-e716. | 1.1 | 10 |
| 24 | MONALEESA clinical program: a review of ribociclib use in different clinical settings. <i>Future Oncology</i> , 2019, 15, 2673-2686. | 1.1 | 21 |
| 25 | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 510. | 1.3 | 49 |
| 26 | PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 659-667. | 1.1 | 17 |
| 27 | Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC. <i>Case Reports in Oncology</i> , 2019, 12, 494-499. | 0.3 | 5 |
| 28 | Achieving Improved Survival Outcomes in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 371-372. | 13.9 | 15 |
| 29 | Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. <i>Frontiers in Pharmacology</i> , 2019, 10, 1235. | 1.6 | 24 |
| 30 | Homeopathic supportive care protocol for oral inhibitors of cyclin dependent kinases 4 and 6 (CDK) Tj ETQq1 1 0.784314 rgBT /Overl 10, e69-e73. | 0.1 | 1 |
| 31 | Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 993-998. | 0.6 | 23 |
| 32 | Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 615-622. | 0.7 | 15 |
| 33 | Update Breast Cancer 2019 Part 5 â€œ Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099. | 0.8 | 16 |
| 34 | CDK4/6 inhibitors in advanced breast cancer, what is beyond?. <i>Oncology Reviews</i> , 2019, 13, 416. | 0.8 | 6 |
| 35 | Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319. | 1.4 | 2 |
| 36 | Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. <i>BioDrugs</i> , 2019, 33, 613-620. | 2.2 | 23 |
| 37 | Can CDK4/6 inhibitors cause fatal lung injury?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 917-919. | 1.1 | 29 |
| 38 | Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. <i>Cancer Management and Research</i> , 2019, Volume 11, 513-524. | 0.9 | 5 |
| 39 | Cyclin-dependent kinase 4/6 inhibitors: what have we learnt across studies, therapy situations and substances. <i>Current Opinion in Obstetrics and Gynecology</i> , 2019, 31, 56-66. | 0.9 | 9 |
| 40 | The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics. <i>Oncology and Therapy</i> , 2019, 7, 1-32. | 1.0 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 41 | Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34. | 0.4 | 2 |
| 42 | Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. Expert Review of Anticancer Therapy, 2019, 19, 569-587. | 1.1 | 21 |
| 44 | QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics. Current Treatment Options in Oncology, 2019, 20, 55. | 1.3 | 24 |
| 45 | Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 2019, 381, 307-316. | 13.9 | 656 |
| 46 | Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 2019, 176, 483-494. | 1.1 | 28 |
| 47 | PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?. Future Oncology, 2019, 15, 1407-1410. | 1.1 | 4 |
| 48 | The Role of CDK4/6 Inhibitors in Breast Cancer. Current Treatment Options in Oncology, 2019, 20, 52. | 1.3 | 39 |
| 49 | Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. Current Breast Cancer Reports, 2019, 11, 52-66. | 0.5 | 1 |
| 50 | Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity. Breast, 2019, 46, 70-74. | 0.9 | 49 |
| 51 | An analysis of available biomarker data for targeting cyclin-dependent kinases 4 and 6 (CDK4/6) in breast cancer. Expert Review of Precision Medicine and Drug Development, 2019, 4, 129-138. | 0.4 | 1 |
| 52 | Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. International Journal of Molecular Sciences, 2019, 20, 2353. | 1.8 | 24 |
| 53 | Dependency of Cholangiocarcinoma on Cyclin Dê€“Dependent Kinase Activity. Hepatology, 2019, 70, 1614-1630. | 3.6 | 22 |
| 54 | Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983386. | 1.4 | 39 |
| 55 | Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Research and Treatment, 2019, 176, 429-434. | 1.1 | 51 |
| 56 | Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591982771. | 1.4 | 38 |
| 57 | Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Research and Treatment, 2019, 175, 775-779. | 1.1 | 34 |
| 58 | Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections, 2019, 8, R10-R26. | 0.8 | 33 |
| 59 | Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptorâ€“Positive/Human Epidermal Receptor 2â€“Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs. Clinical Breast Cancer, 2019, 19, e519-e521. | 1.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 62 | Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019, 11, 1661. | 1.7 | 48 |
| 63 | The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. <i>Cancers</i> , 2019, 11, 1894. | 1.7 | 53 |
| 64 | Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. <i>Current Opinion in Oncology</i> , 2019, 31, 122-130. | 1.1 | 18 |
| 65 | Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1205. | 1.3 | 29 |
| 66 | A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 354-369. | 7.7 | 104 |
| 67 | Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2019, 53, 501-509. | 0.9 | 15 |
| 68 | Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value. <i>Breast</i> , 2019, 43, 81-84. | 0.9 | 3 |
| 69 | SEOM clinical guidelines in advanced and recurrent breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 31-45. | 1.2 | 14 |
| 70 | Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. <i>Pharmacological Research</i> , 2019, 139, 471-488. | 3.1 | 270 |
| 71 | Targeting CDK4/6 pathways and beyond in breast cancer. <i>Breast</i> , 2019, 43, 8-17. | 0.9 | 22 |
| 72 | Targeted therapy for breast cancer in older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 380-388. | 0.5 | 9 |
| 73 | Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study. <i>Breast Care</i> , 2020, 15, 289-293. | 0.8 | 2 |
| 74 | Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. <i>Annals of Palliative Medicine</i> , 2020, 9, 1296-1306. | 0.5 | 5 |
| 75 | Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11. | 1.1 | 20 |
| 76 | CDK4/6 inhibitors in breast cancer – from <i>in vitro</i> models to clinical trials. <i>Acta Oncologica</i> , 2020, 59, 219-232. | 0.8 | 8 |
| 77 | Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020, 9, 1025-1032. | 1.3 | 19 |
| 78 | Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145. | 1.1 | 5 |
| 79 | Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. <i>Breast Care</i> , 2020, 15, 408-414. | 0.8 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 80 | CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: A meta-analysis of randomized controlled trials. <i>Breast Journal</i> , 2020, 26, 1439-1443. | 0.4 | 12 |
| 81 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524. | 13.9 | 482 |
| 82 | The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013. <i>Cancer</i> , 2020, 126, 971-977. | 2.0 | 3 |
| 83 | Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. <i>Breast</i> , 2020, 49, 55-62. | 0.9 | 49 |
| 84 | Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2020312. | 2.8 | 48 |
| 85 | Can we cure oligometastatic disease? A practical point of view. <i>Current Opinion in Oncology</i> , 2020, 32, 568-574. | 1.1 | 5 |
| 86 | Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. <i>Current Heart Failure Reports</i> , 2020, 17, 397-408. | 1.3 | 12 |
| 87 | Developing themes in targeted therapies for hormone receptor-positive breast cancer. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020, 15, 15-23. | 0.6 | 0 |
| 88 | Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer - results from a real-world setting. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100201. | 0.7 | 4 |
| 89 | Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 90, 102086. | 3.4 | 29 |
| 90 | Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study. <i>Breast</i> , 2020, 54, 148-154. | 0.9 | 25 |
| 91 | Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1501-1520. | 1.6 | 43 |
| 92 | ABC4 Consensus: First Latin American Meeting - Assessment, Comments, and Application of Its Recommendations. <i>JCO Global Oncology</i> , 2020, 6, 819-827. | 0.8 | 2 |
| 93 | Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 580251. | 1.6 | 38 |
| 94 | Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Journal of Cancer</i> , 2020, 11, 7127-7136. | 1.2 | 11 |
| 95 | Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 855-866. | 0.8 | 11 |
| 96 | Ribociclib therapy in peritoneal carcinomatosis secondary to HER2-negative metastatic breast cancer: A clinical case with a positive outcome. <i>Breast Journal</i> , 2020, 26, 1808-1810. | 0.4 | 0 |
| 97 | Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 2763-2778. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 98 | Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. <i>Breast Care</i> , 2020, 15, 347-354. | 0.8 | 46 |
| 99 | Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094306. | 1.4 | 44 |
| 100 | Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 2338-2345. | 0.9 | 8 |
| 101 | Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis. <i>ESMO Open</i> , 2020, 5, e000842. | 2.0 | 16 |
| 102 | Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. <i>Drugs</i> , 2020, 80, 1685-1697. | 4.9 | 72 |
| 103 | Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6479. | 1.8 | 71 |
| 104 | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6400. | 1.8 | 50 |
| 105 | POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. <i>Future Oncology</i> , 2020, 16, 2475-2485. | 1.1 | 9 |
| 106 | Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. <i>Acta Oncologica</i> , 2020, 59, 1382-1387. | 0.8 | 11 |
| 107 | Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096725. | 1.4 | 0 |
| 108 | Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 3-14. | 0.7 | 3 |
| 109 | Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?. <i>Current Oncology Reports</i> , 2020, 22, 57. | 1.8 | 26 |
| 110 | Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies. <i>Cancer</i> , 2020, 126, 3400-3416. | 2.0 | 19 |
| 111 | What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 55-70. | 1.8 | 13 |
| 112 | Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. <i>Chinese Medical Journal</i> , 2020, 133, 1099-1108. | 0.9 | 17 |
| 113 | Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors. <i>British Journal of Cancer</i> , 2020, 123, 176-177. | 2.9 | 4 |
| 114 | Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 777-789. | 1.9 | 17 |
| 115 | Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteosarcoma. <i>JCO Precision Oncology</i> , 2020, 4, 498-504. | 1.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 116 | Ribociclib-Induced Radiation Recall Dermatitis Following Stereotactic Body Radiation Therapy: Case Report and Literature Review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 353-354. | 0.6 | 5 |
| 117 | Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097. | 3.0 | 59 |
| 118 | Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308. | 1.8 | 3 |
| 119 | Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 3477-3487. | 0.9 | 40 |
| 120 | Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. <i>Drug Discovery Today</i> , 2020, 25, 1580-1584. | 3.2 | 3 |
| 121 | Retinoblastoma protein expression and its predictors in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 19. | 2.3 | 23 |
| 122 | Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 563-573. | 1.1 | 2 |
| 123 | Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0233571. | 1.1 | 16 |
| 124 | Palbociclib and beyond for the treatment of HR+HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. <i>Current Medical Research and Opinion</i> , 2020, 36, 1363-1373. | 0.9 | 5 |
| 125 | An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00599. | 1.1 | 17 |
| 126 | Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 45-56. | 1.0 | 15 |
| 127 | Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18. | 1.3 | 72 |
| 128 | Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 199-209. | 1.1 | 19 |
| 129 | The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1486-1491. | 0.5 | 12 |
| 130 | Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , 2020, 15, e0228822. | 1.1 | 26 |
| 131 | A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204. | 1.0 | 5 |
| 132 | High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors. <i>International Journal of Breast Cancer</i> , 2020, 2020, 1-7. | 0.6 | 2 |
| 133 | Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2020, 9, 657-668. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 134 | Biologic therapy for advanced breast cancer: recent advances and future directions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1009-1024. | 1.4 | 23 |
| 135 | Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957. | 3.2 | 54 |
| 136 | Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4120-4134. | 3.2 | 65 |
| 137 | Ribociclib-Induced Pneumonitis: A Case Report. <i>Breast Care</i> , 2021, 16, 307-311. | 0.8 | 5 |
| 138 | Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer—Is Not Worse Good Enough?. <i>JAMA Oncology</i> , 2021, 7, 30. | 3.4 | 1 |
| 139 | Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. <i>Cancer Reports</i> , 2021, 4, e1308. | 0.6 | 7 |
| 140 | PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. <i>Pharmacological Research</i> , 2021, 163, 105241. | 3.1 | 23 |
| 141 | RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 191-206. | 2.9 | 16 |
| 142 | CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 283-298. | 1.1 | 39 |
| 143 | CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136. | 3.4 | 25 |
| 144 | Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review. <i>Advances in Therapy</i> , 2021, 38, 109-136. | 1.3 | 23 |
| 145 | SOLAR1s: alpelisib returns to earth?. <i>Annals of Oncology</i> , 2021, 32, 129-132. | 0.6 | 2 |
| 146 | Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. <i>Translational Oncology</i> , 2021, 14, 100939. | 1.7 | 18 |
| 147 | Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106. | 1.1 | 9 |
| 148 | Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428. | 3.2 | 16 |
| 149 | First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. <i>Breast Care</i> , 2021, 16, 129-134. | 0.8 | 3 |
| 150 | Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. <i>Breast Care</i> , 2021, 16, 115-128. | 0.8 | 10 |
| 151 | Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2~ locally advanced or metastatic breast cancer: a Brazilian private payer perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110005. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 152 | Cardiovascular Oncologic Emergencies. , 2021, , 269-290. | | 0 |
| 153 | CDK4/6 inhibitor plus endocrine therapy for hormone receptorâ€positive, HER2â€negative metastatic breast cancer: The new standard of care. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-14. | 0.7 | 11 |
| 154 | CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers, 2021, 13, 332. | 1.7 | 35 |
| 156 | Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer. Cancers, 2021, 13, 369. | 1.7 | 35 |
| 157 | Frontiers in HER2-positive breast cancer in 2020. Current Opinion in Obstetrics and Gynecology, 2021, 33, 48-52. | 0.9 | 1 |
| 159 | Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. Npj Breast Cancer, 2021, 7, 8. | 2.3 | 14 |
| 160 | Clinical application of circulating tumor DNA in breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1431-1442. | 1.2 | 5 |
| 161 | Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR). BMC Cancer, 2021, 21, 303. | 1.1 | 13 |
| 162 | Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. Therapeutics and Clinical Risk Management, 2021, Volume 17, 193-207. | 0.9 | 34 |
| 163 | Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients. Scientific Reports, 2021, 11, 6761. | 1.6 | 16 |
| 164 | Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2021, 61, 1001-1009. | 1.0 | 6 |
| 165 | The Way of the Future: Personalizing Treatment Plans Through Technology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 12-23. | 1.8 | 8 |
| 166 | Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2â€ metastastatic breast cancer. Breast Cancer Research and Treatment, 2021, 188, 799-809. | 1.1 | 11 |
| 167 | CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686. | 1.5 | 20 |
| 168 | Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trialâ€PEARL. Annals of Oncology, 2021, 32, 488-499. | 0.6 | 69 |
| 169 | Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2â€ ABC Patients: A Systematic Review and Meta-Analysis. Cancer Investigation, 2021, 39, 369-378. | 0.6 | 7 |
| 170 | Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies. JCO Global Oncology, 2021, 7, 474-485. | 0.8 | 2 |
| 172 | Adjuvant cyclinâ€dependent kinase 4/6 inhibition in hormone receptorâ€positive breast cancer: One Monarch to rule them all?. Cancer, 2021, 127, 3302-3309. | 2.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 173 | Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms. <i>Frontiers in Oncology</i> , 2021, 11, 651541. | 1.3 | 8 |
| 174 | Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822. | 0.9 | 24 |
| 175 | Liquid Biopsy: A New Tool for Overcoming CDKi Resistance Mechanisms in Luminal Metastatic Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 407. | 1.1 | 3 |
| 176 | Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 2650. | 1.7 | 11 |
| 177 | Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. <i>Journal of Clinical Oncology</i> , 2021, 39, 1458-1467. | 0.8 | 73 |
| 178 | Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2929-2939. | 1.0 | 3 |
| 180 | Optimal integration of CDK4/6 inhibitors for treatment of hormone receptor-positive metastatic breast cancer. <i>Practical Oncology</i> , 2021, 4, 11-18. | 0.1 | 0 |
| 181 | First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021, 57, 104-112. | 0.9 | 14 |
| 182 | First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta. <i>Current Oncology</i> , 2021, 28, 2270-2280. | 0.9 | 4 |
| 183 | Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 679-686. | 2.9 | 31 |
| 184 | Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement from the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e000082. | 1.6 | 55 |
| 185 | Oligometastatic Breast Cancer: How to Manage It?. <i>Journal of Personalized Medicine</i> , 2021, 11, 532. | 1.1 | 8 |
| 186 | Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 643155. | 1.3 | 13 |
| 187 | Post San Antonio updateâ€”my top three abstracts!. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 244-246. | 0.3 | 1 |
| 188 | Predicting optimal treatment regimens for patients with HR+/HER2-Âbreast cancer using machine learning based on electronic health records. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 777-795. | 0.6 | 3 |
| 189 | CDK 4/6 inhibitor induced lung injury: a case report and review of literature. <i>Ecancermedicalsecience</i> , 2021, 15, 1245. | 0.6 | 4 |
| 190 | Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671. | 5.7 | 34 |
| 191 | Drug induced vitiligoâ€”like depigmentation from a CDK 4/6 inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, . | 0.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 192 | Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature. <i>Clinical Breast Cancer</i> , 2022, 22, e65-e73. | 1.1 | 10 |
| 193 | Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 693104. | 1.3 | 67 |
| 194 | CDK4/6 inhibitor-induced colitis: a case report and review of the literature. <i>BMJ Case Reports</i> , 2021, 14, e242766. | 0.2 | 2 |
| 195 | Landmark trials in the medical oncology management of metastatic breast cancer. <i>Seminars in Oncology</i> , 2021, 48, 246-258. | 0.8 | 4 |
| 196 | Precision medicine in breast cancer: From clinical trials to clinical practice. <i>Cancer Treatment Reviews</i> , 2021, 98, 102223. | 3.4 | 34 |
| 197 | Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3959-3977. | 0.8 | 121 |
| 198 | Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer. <i>Cancers</i> , 2021, 13, 3517. | 1.7 | 68 |
| 199 | Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87. | 2.2 | 21 |
| 200 | Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?. <i>Clinical Breast Cancer</i> , 2022, 22, 191-199. | 1.1 | 8 |
| 201 | MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 4114. | 1.7 | 10 |
| 202 | Hormonoterapia en c ncer de mama metast sico. Revisi n de la Evidencia y Abordaje Terap utico en el Instituto Nacional de Cancerolog a, Bogot  - Colombia. <i>Revista Colombiana De Cancerolog a</i> , 0, 25, 142-151. | 0.0 | 0 |
| 203 | Breast Cancer Treatments: Updates and New Challenges. <i>Journal of Personalized Medicine</i> , 2021, 11, 808. | 1.1 | 108 |
| 204 | Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. <i>Clinical and Translational Oncology</i> , 2022, 24, 161-192. | 1.2 | 31 |
| 205 | The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients. <i>Anti-Cancer Drugs</i> , 2022, 33, e628-e634. | 0.7 | 4 |
| 206 | Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting. <i>BMC Proceedings</i> , 2021, 15, 15. | 1.8 | 5 |
| 207 | The Effects of HER2 on CDK4/6 Activity in Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e278-e285. | 1.1 | 8 |
| 208 | The role of CDK4/6 inhibitors in early breast cancer. <i>Breast</i> , 2021, 58, 160-169. | 0.9 | 18 |
| 209 | The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. <i>Anti-Cancer Drugs</i> , 2022, 33, e635-e643. | 0.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 210 | Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 689-699. | 1.1 | 21 |
| 211 | Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. <i>JCO Precision Oncology</i> , 2021, 5, 1408-1420. | 1.5 | 15 |
| 212 | Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience. <i>Cancers</i> , 2021, 13, 4163. | 1.7 | 3 |
| 213 | Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. <i>JAMA Oncology</i> , 2021, 7, e213428. | 3.4 | 18 |
| 214 | Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study. <i>ESMO Open</i> , 2021, 6, 100226. | 2.0 | 3 |
| 215 | The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1105-1124. | 1.1 | 26 |
| 216 | A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. <i>Breast Cancer Management</i> , 2021, 10, BMT59. | 0.2 | 2 |
| 217 | From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data. <i>Journal of Chemotherapy</i> , 2021, , 1-6. | 0.7 | 0 |
| 218 | 6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapies. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 6, 111-117. | 0.0 | 0 |
| 220 | Combined endocrine and targeted therapy in luminal breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1237-1251. | 1.1 | 12 |
| 221 | Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials. <i>Breast</i> , 2021, 59, 165-175. | 0.9 | 8 |
| 222 | The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002. | | 0 |
| 223 | Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. <i>Cancers</i> , 2021, 13, 465. | 1.7 | 7 |
| 224 | Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100606. | 1.0 | 11 |
| 225 | Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. <i>Oncolmmunology</i> , 2020, 9, 1710052. | 2.1 | 17 |
| 226 | Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428. | 3.2 | 11 |
| 227 | Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, R15-R30. | 1.6 | 96 |
| 228 | CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. <i>Oncotarget</i> , 2018, 9, 34193-34195. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 229 | New drug: Ribociclib for breast cancer. Australian Prescriber, 2018, 41, 172. | 0.5 | 4 |
| 230 | Ribociclib for the treatment of hormone-positive HER2-negative breast cancer. Meditsinskiy Sovet, 2019, , 72-80. | 0.1 | 3 |
| 231 | The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer. Forum of Clinical Oncology, 2019, 10, 2-14. | 0.1 | 3 |
| 232 | Hormonal therapy in premenopausal patients with SR-positive, HER2-negative breast cancer. Onkologie (Czech Republic), 2019, 13, 24-28. | 0.0 | 1 |
| 233 | HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE. South Russian Journal of Cancer, 2020, 1, 46-51. | 0.1 | 8 |
| 234 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478. | 2.3 | 848 |
| 235 | A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context, 2018, 7, 1-6. | 1.0 | 8 |
| 236 | The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clinical Breast Cancer, 2022, 22, 223-234. | 1.1 | 2 |
| 237 | Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer. JAMA Oncology, 2021, 7, 1791. | 3.4 | 56 |
| 238 | Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Medicinal Research Reviews, 2022, 42, 654-709. | 5.0 | 21 |
| 239 | Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 191, 191-207. | 1.1 | 0 |
| 240 | Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review. Expert Review of Anticancer Therapy, 2021, 21, 1399-1410. | 1.1 | 0 |
| 241 | Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. Cancers, 2021, 13, 4972. | 1.7 | 9 |
| 242 | Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER+/HER2- Breast Cancer. Clinical Cancer Research, 2022, 28, 163-174. | 3.2 | 8 |
| 243 | Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers, 2021, 13, 5198. | 1.7 | 10 |
| 244 | Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer. Breast, 2021, 60, 163-167. | 0.9 | 17 |
| 245 | PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER. Opuholi Zenskoj Reproktivnoy Sistem, 2018, 14, 21-35. | 0.1 | 2 |
| 246 | Endocrine Therapy of Metastatic Breast Cancer. , 2019, , 533-555. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 247 | Systemic Treatment Drugs and Regimens. , 2019, , 587-608. | | 0 |
| 248 | Systemic Treatment Drugs/Regimens and Dose Modifications. , 2019, , 789-801. | | 0 |
| 249 | Breast Cancer in Older Women. , 2019, , 325-335. | | 1 |
| 250 | Treatment of Metastatic Breast Cancer: Endocrine Therapy. , 2019, , 419-447. | | 0 |
| 251 | Cyclin-dependent kinase inhibitors: efficacy and safety. Meditsinskiy Sovet, 2019, , 42-55. | 0.1 | 2 |
| 252 | Neurological Complications of Targeted Therapies. , 2020, , 341-363. | | 0 |
| 253 | Protocole homœopathique d'accompagnement des inhibiteurs oraux des kinases dépendantes des cyclines 4 et 6 (CDK 4/6), dans le cancer du sein post-ménopausique métastatique hormonodépendant. Revue D'Homeopathie, 2019, 10, 193-198. | 0.1 | 0 |
| 255 | Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer. Farmakoekonomika, 2020, 12, 279-290. | 0.4 | 1 |
| 256 | Hormone Receptor-Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices. Journal of the Advanced Practitioner in Oncology, 2020, 11, 275-279. | 0.2 | 0 |
| 258 | Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience. Journal of Modern Oncology, 2020, 22, 98-103. | 0.1 | 0 |
| 259 | Clinical aspects of the use of ribociclib. Meditsinskiy Sovet, 2020, , 44-56. | 0.1 | 0 |
| 260 | Abemaciclib—¼ for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ⁻) metastatic breast cancer. Cancer Nursing Practice, 0, , . | 0.2 | 0 |
| 261 | Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?. Journal of Clinical Oncology, 2021, 39, 3890-3896. | 0.8 | 0 |
| 262 | Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2 ⁻ Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers, 2021, 13, 5397. | 1.7 | 7 |
| 263 | U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. Clinical Cancer Research, 2022, 28, 1072-1086. | 3.2 | 31 |
| 264 | Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clinical Cancer Research, 2022, 28, 821-830. | 3.2 | 26 |
| 265 | Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene. Meditsinskiy Sovet, 2020, , 40-46. | 0.1 | 1 |
| 266 | Management of Advanced Breast Cancer in Young Women: What's New in Systemic Treatment. , 2020, , 127-142. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 267 | Potential aromatase inhibitors and antiestrogen agents based on stilbene and stilbazole derivatives. Proceedings of the National Academy of Sciences of Belarus, Chemical Series, 2020, 56, 81-87. | 0.1 | 0 |
| 268 | A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6 Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated Meta-analysis. Korean Journal of Clinical Pharmacy, 2020, 30, 1-10. | 0.0 | 0 |
| 269 | Post-neoadjuvant treatment of breast cancer. Meditsinskiy Sovet, 2020, , 232-241. | 0.1 | 0 |
| 270 | ESR1 mutation as potential predictive marker for choice of treatment tactics in hormone-resistant HR+/HER2-negative breast cancer. Medical Alphabet, 2020, , 68-73. | 0.0 | 1 |
| 271 | A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. American Journal of Cancer Research, 2018, 8, 2359-2376. | 1.4 | 24 |
| 272 | Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement. Cancers, 2021, 13, 5643. | 1.7 | 16 |
| 274 | A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor—positive Breast Cancer, SWOG S1222. Clinical Cancer Research, 2022, 28, 611-617. | 3.2 | 4 |
| 275 | Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncology Letters, 2021, 23, 25. | 0.8 | 10 |
| 276 | Genomic characterization of de novo metastatic breast cancer. Clinical Breast Cancer, 2021, , . | 1.1 | 1 |
| 277 | Systematic review and meta-analysis of post-progression outcomes in ER+/HER2— metastatic breast cancer after CDK4/6 inhibitors within randomized clinical trials. ESMO Open, 2021, 6, 100332. | 2.0 | 16 |
| 278 | Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 190-197. | 0.8 | 9 |
| 279 | Adjuvant abemaciclib for high-risk breast cancer: the story continues. Annals of Oncology, 2021, 32, 1457-1459. | 0.6 | 2 |
| 280 | Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2—) breast cancer: a systematic review. Annals of Translational Medicine, 2022, 10, 233-233. | 0.7 | 5 |
| 281 | Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor—Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. Clinical Cancer Research, 2022, 28, 1107-1116. | 3.2 | 7 |
| 282 | Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2— patients with metastatic breast cancer. Medicine (United States), 2021, 100, e27710. | 0.4 | 2 |
| 283 | Lineage-specific silencing of PSAT1 induces serine auxotrophy and sensitivity to dietary serine starvation in luminal breast tumors. Cell Reports, 2022, 38, 110278. | 2.9 | 14 |
| 284 | PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers, 2022, 14, 599. | 1.7 | 8 |
| 285 | Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland and Spain. Future Oncology, 2022, 18, 1115-1132. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 286 | Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). <i>European Journal of Cancer</i> , 2022, 161, 26-37. | 1.3 | 11 |
| 287 | Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. <i>Current Problems in Cancer</i> , 2022, 46, 100832. | 1.0 | 2 |
| 288 | Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100002. | 1.5 | 36 |
| 289 | Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 37-44. | 2.3 | 7 |
| 291 | Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. <i>Clinical and Translational Oncology</i> , 2022, 24, 1033-1046. | 1.2 | 5 |
| 292 | Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108. | | 25 |
| 293 | Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. <i>International Journal of Cancer</i> , 2022, 150, 2025-2037. | 2.3 | 16 |
| 294 | CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. <i>Future Oncology</i> , 2022, 18, 1143-1157. | 1.1 | 8 |
| 295 | The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 797157. | 1.3 | 1 |
| 296 | Ribociclib-associated organising pneumonia. <i>BMJ Case Reports</i> , 2021, 14, e245187. | 0.2 | 1 |
| 297 | AMEERA-5: a randomized, double-blind phase 3 study of amcnestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210839. | 1.4 | 16 |
| 298 | PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. <i>Future Oncology</i> , 2022, 18, 1805-1816. | 1.1 | 10 |
| 299 | Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb ComplEEment-1 trial. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 95-103. | 1.1 | 8 |
| 300 | Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 343-351. | 1.1 | 6 |
| 301 | Ultrasonic Omics Based on Intelligent Classification Algorithm in Hormone Receptor Expression and Efficacy Evaluation of Breast Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 1-8. | 0.7 | 2 |
| 302 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950. | 13.9 | 220 |
| 303 | Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data. <i>Cancer Management and Research</i> , 2022, Volume 14, 1033-1041. | 0.9 | 8 |
| 305 | How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. <i>Life</i> , 2022, 12, 378. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 306 | Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?. <i>Lancet Oncology, The</i> , 2022, 23, 325-328. | 5.1 | 1 |
| 307 | A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. <i>Npj Breast Cancer</i> , 2022, 8, 35. | 2.3 | 7 |
| 308 | 18F-FDG PET/CT Metabolic Response With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent 4/6 Kinase Inhibitors. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, . | 0.7 | 4 |
| 309 | Ribociclib-Induced Pseudo-Acute Kidney Injury. <i>Journal of Onco-Nephrology</i> , 0, , 239936932210852. | 0.3 | 4 |
| 310 | Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China. <i>BMC Cancer</i> , 2022, 22, 385. | 1.1 | 10 |
| 311 | Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. <i>Cancers</i> , 2022, 14, 196. | 1.7 | 4 |
| 312 | Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. <i>Breast</i> , 2022, 62, S70-S79. | 0.9 | 10 |
| 313 | Clinical case of the treatment of metastatic luminal breast cancer. <i>Meditinskiy Sovet</i> , 2021, , 160-166. | 0.1 | 0 |
| 314 | Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. <i>Breast Cancer: Targets and Therapy</i> , 2022, Volume 14, 101-111. | 1.0 | 2 |
| 315 | Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. <i>European Journal of Cancer</i> , 2022, 168, 12-24. | 1.3 | 9 |
| 316 | Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines. <i>Cancer Research</i> , 2022, 82, 2171-2184. | 0.4 | 12 |
| 318 | Cancer as a new chronic disease: Oncology nursing in the 21st Century.. <i>Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique</i> , 2022, 32, 87-92. | 0.1 | 0 |
| 319 | Real world incidence and management of adverse events in patients with HR+, HER2+ metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting. <i>Current Medical Research and Opinion</i> , 2022, 38, 1319-1331. | 0.9 | 9 |
| 320 | Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. <i>BMC Cancer</i> , 2022, 22, 516. | 1.1 | 11 |
| 321 | Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b ComplEement-1 trial. <i>Radiology and Oncology</i> , 2022, 56, 238-247. | 0.6 | 3 |
| 323 | VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. <i>Clinical Cancer Research</i> , 2022, 28, 3256-3267. | 3.2 | 28 |
| 324 | Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. <i>Annals of Oncology</i> , 2022, 33, 769-785. | 0.6 | 37 |
| 325 | Changes in Body Adiposity in Women Undergoing Breast Cancer Treatment: A Scoping Review. <i>Nutrition and Cancer</i> , 0, , 1-15. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 326 | NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 561-565. | 2.3 | 4 |
| 327 | Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis. BMJ Open, 2022, 12, e056374. | 0.8 | 3 |
| 329 | Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211008. | 1.4 | 0 |
| 330 | Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361. | 0.5 | 2 |
| 331 | Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Clinical Obstetrics and Gynecology, 2022, 65, 461-481. | 0.6 | 6 |
| 332 | Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 805-814. | 1.1 | 2 |
| 333 | Arrhythmic Complications Associated with Cancer Therapies. Heart Failure Clinics, 2022, 18, 375-383. | 1.0 | 2 |
| 334 | Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathology and Oncology Research, 0, 28, . | 0.9 | 12 |
| 335 | Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 7079. | 1.8 | 4 |
| 336 | Prediction for Distant Metastasis of Breast Cancer Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Images under Deep Learning. Computational Intelligence and Neuroscience, 2022, 2022, 1-7. | 1.1 | 5 |
| 337 | Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice. JCO Precision Oncology, 2022, , . | 1.5 | 4 |
| 339 | Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. Expert Opinion on Investigational Drugs, 2022, 31, 933-944. | 1.9 | 0 |
| 340 | Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study. , 2022, 39, . | | 27 |
| 341 | Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. Cancers, 2022, 14, 3774. | 1.7 | 10 |
| 342 | Work productivity among patients with metastatic breast cancer in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 0, , 1-9. | 0.7 | 0 |
| 343 | Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. Journal of Drug Assessment, 2022, 11, 12-19. | 1.1 | 2 |
| 344 | Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy. Journal of Oncology Pharmacy Practice, 2023, 29, 764-767. | 0.5 | 0 |
| 345 | HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study. Frontiers in Endocrinology, 0, 13, . | 1.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 347 | Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer. <i>JCI Insight</i> , 2022, 7, . | 2.3 | 6 |
| 348 | CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 3 |
| 349 | Targeted therapy for breast cancer: An overview of drug classes and outcomes. <i>Biochemical Pharmacology</i> , 2022, 204, 115209. | 2.0 | 38 |
| 350 | Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2 ⁻ Breast Cancer Based on a Window of Opportunity Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 4255-4267. | 1.0 | 0 |
| 351 | Controversial topics in metastatic HR+/HER2 ⁻ breast cancer: Guiding treatment by a modified Delphi approach. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 0 |
| 352 | Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use. <i>Journal of Breast Cancer</i> , 2022, 25, 296. | 0.8 | 1 |
| 353 | CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review). <i>International Journal of Molecular Medicine</i> , 2022, 50, . | 1.8 | 15 |
| 354 | Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2 ⁻ Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b ComPLEEment-1 Study. <i>Targeted Oncology</i> , 0, , . | 1.7 | 1 |
| 355 | Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2 ⁻ Metastatic Breast Cancer Treated with Abemaciclib. <i>Drugs - Real World Outcomes</i> , 2022, 9, 681-693. | 0.7 | 4 |
| 356 | Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , . | 0.7 | 0 |
| 357 | Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer. <i>Npj Precision Oncology</i> , 2022, 6, . | 2.3 | 10 |
| 358 | Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR ⁺) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling. <i>Current Breast Cancer Reports</i> , 0, , . | 0.5 | 0 |
| 359 | Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 2933-2948. | 2.0 | 21 |
| 360 | Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451. | 4.9 | 5 |
| 361 | Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors. <i>Anticancer Research</i> , 2022, 42, 4867-4878. | 0.5 | 2 |
| 362 | Clinical outcomes of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in patients with male breast cancer: A multicenter study. <i>Breast</i> , 2022, 66, 85-88. | 0.9 | 4 |
| 363 | Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2 ⁻ advanced breast cancer: Results from the Spanish sub-population of the phase 3b ComPLEEment-1 trial. <i>Breast</i> , 2022, 66, 77-84. | 0.9 | 3 |
| 364 | A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer. , 2022, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 366 | A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancers</i> , 2022, 14, 4996. | 1.7 | 0 |
| 367 | Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b Complement-1 Trial. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 351-362. | 1.0 | 0 |
| 368 | Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. <i>Oncologist</i> , 2023, 28, 23-32. | 1.9 | 6 |
| 369 | Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, . | 3.1 | 25 |
| 370 | Clinical Characteristics and Survival Outcomes of Patients with De Novo Metastatic Breast Cancer. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 363-373. | 1.0 | 3 |
| 371 | ESR1 activating mutations: From structure to clinical application. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188830. | 3.3 | 10 |
| 372 | Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. <i>Breast</i> , 2022, 66, 157-161. | 0.9 | 4 |
| 373 | The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2022, 76, 333. | 0.4 | 1 |
| 374 | The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 169-181. | 0.9 | 3 |
| 375 | Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report. <i>Journal of Modern Oncology</i> , 2022, 24, 373-379. | 0.1 | 0 |
| 376 | Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil. <i>Revista De Saude Publica</i> , 0, 56, 100. | 0.7 | 0 |
| 377 | Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study. <i>Breast Cancer</i> , 2023, 30, 282-292. | 1.3 | 3 |
| 378 | Case report: 18F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 379 | Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2022, 14, 6100. | 1.7 | 4 |
| 380 | CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature. <i>Current Oncology</i> , 2022, 29, 9630-9639. | 0.9 | 0 |
| 381 | Therapeutic drug monitoring in breast cancer therapy - LC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, 225, 115211. | 1.4 | 8 |
| 382 | Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1619-1627. | 0.5 | 2 |
| 383 | Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases. <i>Meditsinskiy Sovet</i> , 2022, , 42-51. | 0.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 385 | How I treat HER2-low advanced breast cancer. <i>Breast</i> , 2023, 67, 116-123. | 0.9 | 5 |
| 386 | Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 1 |
| 387 | Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. <i>Cancers</i> , 2023, 15, 316. | 1.7 | 3 |
| 388 | A rapid reduction in tumor size by cyclin-dependent kinase inhibition in hormone receptor-positive postpartum breast cancer: a case report of two patients and a review of the literature. <i>Annals of Translational Medicine</i> , 2022, 10, 1413-1413. | 0.7 | 0 |
| 389 | Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer. <i>Cancers</i> , 2023, 15, 690. | 1.7 | 5 |
| 390 | The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-8. | 1.1 | 0 |
| 391 | Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors. <i>Frontiers in Oncology</i> , 0, 12, . | 1.3 | 2 |
| 392 | Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2023, 45, 327-336. | 1.0 | 6 |
| 394 | CDK4/6 Inhibitorsâ€”Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 1763. | 1.7 | 4 |
| 395 | Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10â€”year, singleâ€”center, realâ€”world study of 67 cases. <i>Cancer Medicine</i> , 0, , . | 1.3 | 2 |
| 396 | The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis. <i>EClinicalMedicine</i> , 2023, 56, 101824. | 3.2 | 1 |
| 397 | Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective. <i>Biomedicines</i> , 2023, 11, 510. | 1.4 | 0 |
| 398 | Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands. <i>JAMA Network Open</i> , 2023, 6, e2256170. | 2.8 | 0 |
| 399 | Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials. <i>Clinical Pharmacokinetics</i> , 2023, 62, 493-504. | 1.6 | 4 |
| 400 | Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2â€” advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. <i>Journal of Medical Economics</i> , 2023, 26, 357-365. | 1.0 | 3 |
| 401 | Advances in medical treatment of breast cancer in 2022. , 2023, 2, 1-17. | | 2 |
| 402 | Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, . | 1.1 | 1 |
| 403 | Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4522. | 1.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-------|-----------|
| 405 | Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature. <i>Diagnosics</i> , 2023, 13, 987. | 1.3 | 5 |
| 406 | HR+/HER2— de novo metastatic breast cancer: a true peculiar entity?. <i>Drugs in Context</i> , 0, 12, 1-19. | 1.0 | 2 |
| 407 | Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases. <i>Journal of Clinical Medicine</i> , 2023, 12, 2044. | 1.0 | 1 |
| 408 | Systematic review of the management of brain metastases from hormone receptor positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2023, 162, 45-57. | 1.4 | 6 |
| 409 | Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?. <i>Medicina (Lithuania)</i> , 2023, 59, 557. | 0.8 | 1 |
| 410 | Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2— Metastatic Breast Cancer in Postmenopausal Women in the USA. <i>Pharmacoeconomics</i> , 2023, 41, 709-718. | 1.7 | 6 |
| 411 | Novel therapeutics in low-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 377-384. | 1.2 | 4 |
| 412 | Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets. <i>Cancers</i> , 2023, 15, 1855. | 1.7 | 1 |
| 413 | Systemic therapy for hormone receptor—positive/human epidermal growth factor receptor 2—negative early stage and metastatic breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 480-515. | 157.7 | 23 |
| 414 | CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, . | 1.8 | 6 |
| 415 | Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells. <i>Cancers</i> , 2023, 15, 1908. | 1.7 | 5 |
| 416 | Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. <i>Cancers</i> , 2023, 15, 2015. | 1.7 | 3 |
| 417 | <sc>CDK4</sc> /6 inhibitor modulating active and quiescent intestinal stem cells for prevention of chemotherapy—induced diarrhea. <i>Journal of Pathology</i> , 0, , . | 2.1 | 1 |
| 418 | Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. <i>Current Oncology Reports</i> , 2023, 25, 689-698. | 1.8 | 2 |
| 419 | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review. <i>Medicina (Lithuania)</i> , 2023, 59, 696. | 0.8 | 1 |
| 420 | A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark. <i>Acta Oncol³gica</i> , 2023, 62, 290-297. | 0.8 | 0 |
| 421 | Second-line Endocrine Therapy of Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis. <i>Current Cancer Drug Targets</i> , 2023, 23, . | 0.8 | 0 |
| 422 | Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 887-900. | 0.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 423 | Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient Preference and Adherence, 0, Volume 17, 1049-1062. | 0.8 | 0 |
| 424 | Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in a Real-World Setting in Taiwan. Value in Health Regional Issues, 2023, 36, 98-104. | 0.5 | 0 |
| 446 | Advancing oncology drug therapies for sub-Saharan Africa. PLOS Global Public Health, 2023, 3, e0001653. | 0.5 | 0 |
| 491 | The CDK4/6 inhibitor revolution â€” a game-changing era for breast cancer treatment. Nature Reviews Clinical Oncology, 2024, 21, 89-105. | 12.5 | 4 |
| 507 | Somatic mutation: Pharmacogenomics in oncology care. , 2024, , 329-356. | | 0 |
| 508 | The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2024, 204, 443-452. | 1.1 | 1 |
| 509 | Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer. Clinical Pharmacokinetics, 2024, 63, 155-170. | 1.6 | 0 |